CVE-2017-17678 — BMC Remedy Mid Tier 9

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

01What is this vulnerability?

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

02Affected products

No structured affected-product list available — see references below for vendor advisories.

03Active exploitation status

Not currently listed on the CISA Known Exploited Vulnerabilities (KEV) catalog. EPSS is the best forward-looking signal — see the EPSS row above.

04Recommended remediation

• Patch to a fixed version listed in the vendor advisory (see references below).
• Mitigate with WAF rules, network egress filters, or feature flags where the patch is not yet available.
• Hunt historical logs for exploitation indicators — see Detection signatures below.

05Technical details

For the full vendor write-up, exploit chains, and reference implementations, see the references list in section 09.

06Detection signatures

Ask SARA in chat to draft a starting detection for this CVE in your stack of choice.

07Related CVEs

No directly-cited follow-up CVEs in the KB record for this advisory. The references list in section 09 carries the vendor cross-references.

08Timeline

• Published: 2021-05-19T14:15:07.367
• Last modified: 2026-07-09T00:16:49.917

09References

• docs.bmc.com — https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-s…
• seclists.org — https://seclists.org/fulldisclosure/2017/Oct/52
• docs.bmc.com — https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-s…
• seclists.org — https://seclists.org/fulldisclosure/2017/Oct/52